Edgewise Therapeutics Inc. (EWTX)
EWTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | EWTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001710072 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $68.7M cash; operating cash flow -$50.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 109,482,763 (2026-10-31); 105,868,434 a year earlier; 63,461,608 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Denver, Colorado, United States | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $199K, sold $19.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | $1.2B | -$78.3M | $68.7M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | Not filed | -$57.3M | -$42.5M | $72.3M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2026 2026-03-31 | Not filed | -$49.0M | -$42.5M | $33.2M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2025 2025-12-31 | Not filed | -$50.2M | -$38.6M | $61.1M | No debt tags | Needs four quarters | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | Not filed | -$40.7M | -$34.8M | $46.0M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | Not filed | -$36.1M | -$32.6M | $43.4M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2025 2025-03-31 | Not filed | -$40.8M | -$37.9M | $49.9M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2024 2024-12-31 | Not filed | -$39.7M | -$27.0M | $41.7M | No debt tags | Needs four quarters | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-04-02 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report FORM 8-K | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 425 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.0% |
| 1 month | +26.6% |
| 3 months | +6.4% |
| Year to date | +85.1% |
| 1 year | +124.9% |
| From 52-week high | -5.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| COGT | Cogent Biosciences Inc. | $27.44 | -3.92% | $4.8B |
| TVTX | Travere Therapeutics Inc. | $49.70 | -1.88% | $4.8B |
| IONS | Ionis Pharmaceuticals Inc. | $28.01 | -3.61% | $4.7B |
| DNTH | Dianthus Therapeutics Inc. | $89.55 | -2.46% | $5.0B |
| LQDA | Liquidia Corporation | $56.37 | -1.81% | $5.1B |
| PTCT | PTC Therapeutics Inc. | $60.97 | -3.97% | $5.1B |
| ERAS | Erasca Inc. | $15.11 | -3.51% | $5.3B |
| MANE | Veradermics Incorporated | $128.05 | -1.24% | $5.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier